Canadian Generic Pharmaceutical Association (CGPA)
15 meetings with public office holders, Jun 23, 2025 to Apr 13, 2026.
502 meetings on record since the registry opened in 2008.
Meetings over time
- Jun 2025: 2 meetings, with Greg Orencsak, Krista Urchenko, Jocelyne Voisin, Ritu Banerjee
- Jul 2025: 2 meetings, with Mackenzy Metcalfe, Mélanie Joly, Paul Moen, Manuela Tomic
- Aug 2025: 0 meetings
- Sep 2025: 1 meeting, with Greg Orencsak, Pamela Aung-Thin
- Oct 2025: 0 meetings
- Nov 2025: 1 meeting, with Pamela Aung-Thin, Margaret Zimmermann
- Dec 2025: 0 meetings
- Jan 2026: 0 meetings
- Feb 2026: 2 meetings, with Pamela Aung-Thin, Sven Schirmer, Marjorie Michel
- Mar 2026: 5 meetings, with Justine Frame, Jocelyne Voisin, Philip Jennings, Ritu Banerjee, Maggie Chi
- Apr 2026: 2 meetings, with Martin Moen, Shalene Curtis-Micallef, Jocelyne Voisin, Pamela Aung-Thin
Jun 2025peak 5 in a monthApr 2026
Hover or focus a month to see who was met.
What they lobby about
- Health15
- Industry15
- Internal Trade12
- International Relations12
- International Trade12
- Taxation and Finance12
The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.
Who they met
Liberal3 met · 3 meetings
Not in Arena's member list15 met · 24 meetings
- Pamela Aung-Thin
- Jocelyne Voisin
- Greg Orencsak
- Manuela Tomic
- Paul Moen
- Ritu Banerjee
- Justine Frame
- Krista Urchenko
- Mackenzy Metcalfe
- Margaret Zimmermann
- Martin Moen
- Nora Draper
- Philip Jennings
- Shalene Curtis-Micallef
- Sven Schirmer
Health Canada (HC) (16) · Innovation, Science and Economic Development Canada (ISED) (8) · Finance Canada (FIN) (1) · House of Commons (1) · Global Affairs Canada (GAC) (1)
In their own words
- Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
- Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
- Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
Meetings from the Commissioner of Lobbying of Canada. Canada does not require lobbyists to disclose what they spend, so there is no lobbying budget to report here — only the meetings they filed.